AC
ALXN

Alexandria Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Alexandria Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-43
Closed -$6K – 571
2017
Q3 		$6K Buy
43
+37
+617% +$5.03K ﹤0.01% 449
2017
Q2 		$1K Sell
6
-10
-63% -$1.16K ﹤0.01% 602
2017
Q1 		$2K Sell
16
-13
-45% -$1.68K ﹤0.01% 564
2016
Q4 		$4K Sell
29
-59
-67% -$7.22K ﹤0.01% 507
2016
Q3 		$11K Hold
88
– – ﹤0.01% 412
2016
Q2 		$10K Buy
88
+1
+1% +$142 ﹤0.01% 415
2016
Q1 		$12K Buy
87
+2
+2% +$294 ﹤0.01% 400
2015
Q4 		$16K Buy
85
+2
+2% +$349 ﹤0.01% 395
2015
Q3 		$13K Buy
83
+4
+5% +$730 ﹤0.01% 380
2015
Q2 		$14K Buy
79
+5
+7% +$863 ﹤0.01% 383
2015
Q1 		$13K Buy
74
+4
+6% +$724 ﹤0.01% 364
2014
Q4 		$13K Hold
70
– – 0.01% 336
2014
Q3 		$12K Buy
70
+3
+4% +$493 0.01% 330
2014
Q2 		$10K Sell
67
-3
-4% -$474 ﹤0.01% 359
2014
Q1 		$11K Sell
70
-12
-15% -$1.91K ﹤0.01% 354
2013
Q4 		$11K Buy
82
+4
+5% +$480 ﹤0.01% 354
2013
Q3 		$9K Sell
78
-7
-8% -$768 ﹤0.01% 379
2013
Q2 		$8K Buy
+85
New +$8.19K ﹤0.01% 420

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Alexandria Capital's ALXN Position: Q4 2017 in Review

Alexandria Capital sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 43 shares — an estimated $6K sold.

Alexandria Capital first reported a position in ALXN in Q2 2013 and held it in 18 quarters. The position peaked at $16K in Q4 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Alexandria Capital reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Alexandria Capital sold 43 Alexion Pharmaceuticals shares in Q4 2017, an estimated $6K.
  • Alexandria Capital first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Alexandria Capital's Alexion Pharmaceuticals position peaked at $16K in Q4 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Alexandria Capital's 13F filing for Q4 2017, filed 9 Feb 2018.